Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 53
Filtrar
1.
Pak J Biol Sci ; 24(1): 72-79, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-33683033

RESUMEN

BACKGROUND AND OBJECTIVE: Carisoprodol is a relaxant muscular-skeleton associated with sore muscles and appropriate studies have not been performed on carisoprodol effects on fetuses and mothers. This study has been conducted to clarify the treatment with a high and low dosage of carisoprodol (Somadril) on the histopathological, histochemical changes in the fetal ileum of the Albino rats. MATERIALS AND METHODS: In the present research 30 adult pregnant rats have been used and divided into three classes (10 pregnant rats in each group), the first group was the group of Control (C). The 2nd and 3rd groups (S1 and S2) were treated with carisoprodol oral doses equating to 10.8 and 21.6 mg/100 g b.wt. per day, respectively. For 15 days from day 6-20 of pregnancy, groups S1 and S2 are administered. On the 20th day of pregnancy, the pregnant rats were sacrificed and small parts of fetal ileum for histopathological and histochemical studies. RESULTS: Diverse histopathological and histochemical alternations were detected in the fetal ileum tissue of the two groups S1 and S2 after maternal treatment with high and low doses of carisoprodol compared to the control set. CONCLUSION: This study showed that several histopathological and histochemical deformities in the fetal ileum tissues were caused by the administration of carisoprodol.


Asunto(s)
Carisoprodol/toxicidad , Feto/efectos de los fármacos , Íleon/efectos de los fármacos , Relajantes Musculares Centrales/toxicidad , Animales , Femenino , Feto/patología , Edad Gestacional , Íleon/patología , Embarazo , Ratas , Medición de Riesgo
2.
Int J Pharm ; 582: 119344, 2020 May 30.
Artículo en Inglés | MEDLINE | ID: mdl-32315750

RESUMEN

Baclofen is a centrally acting skeletal muscle relaxant approved by the US Food and Drug Administration (FDA) for the treatment of muscle spasticity, but the immediate release mode of administration and rapid absorption has been associated with adverse effects. The main objective of this study was to prepare modified release floating beads of baclofen in order to decrease the unwanted side effects. The beads were prepared using alginate and coated with Eudragit RS100, Eudragit L100 and cetyl alcohol. They were evaluated for their encapsulation efficiency, buoyance characteristics, morphology, and in vitro release. They have also been tested in vivo for their oral bioavailability and potential side effects. The prepared beads showed floating properties up to 12 h with different lag times ranging from 45.67 to 72.33 sec. Morphological evaluation using scanning electron microscopy (SEM) revealed that the coated beads show smooth with no pores or cracks surfaces. Real-time morphology of the beads during in vitro release testing was studied by the SEM. Optimized formulation of baclofen coated beads exhibited favorable mechanical properties, in addition, it provided extended baclofen release for up to 6 h. In addition, in vivo studies showed that the coated beads effectively decreased the hypotensive side effect associated with rapid plasma peaking from Baclofen® immediate-release tablets. In addition, there were significant differences between the values of Cmax, Tmax, and AUC0-24 of optimized modified release baclofen floating formulations when compared to Baclofen® immediate-release tablets.


Asunto(s)
Resinas Acrílicas/química , Baclofeno/administración & dosificación , Portadores de Fármacos , Relajantes Musculares Centrales/administración & dosificación , Ácidos Polimetacrílicos/química , Administración Oral , Animales , Baclofeno/química , Baclofeno/farmacocinética , Baclofeno/toxicidad , Disponibilidad Biológica , Presión Sanguínea/efectos de los fármacos , Preparaciones de Acción Retardada , Composición de Medicamentos , Liberación de Fármacos , Alcoholes Grasos/química , Femenino , Hipotensión/inducido químicamente , Hipotensión/fisiopatología , Relajantes Musculares Centrales/química , Relajantes Musculares Centrales/farmacocinética , Relajantes Musculares Centrales/toxicidad , Conejos , Propiedades de Superficie
3.
Turk Neurosurg ; 29(6): 851-855, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31192442

RESUMEN

AIM: To investigate the effects of Phenyramidol (Phe) on neural development in an early chicken embryo model. MATERIAL AND METHODS: Sixty fertile non-pathogenic Super Nick eggs were incubated for 24 hours (h) and divided into four groups of 15 eggs each. Phe was administrated through the sub-blastoderm, and the eggs were incubated for another 24 h. All eggs were opened after 48 h of incubation, and the embryos were evaluated morphologically and histopathologically. RESULTS: In Group 1 (control group), none exhibited neural tube defects (NTDs) (0%), 1 (6.6%) was undeveloped; in Group 2 (low dosages), 1 did not develop (6.6%); in Group 3 (normal dosages), 2 (13.4%) had NTDs, 1 (6.6%) was undeveloped; in Group 4 (high dosages), 5 (33.3%) had NTDs, 2 (13.3%) were undeveloped. CONCLUSION: In light of the results, it was determined that the use of increasing doses of Phe led to defects in midline closure in early chicken embryos. This is the first report in the literature on Phe used in an early chicken embryo model.


Asunto(s)
Desarrollo Embrionario/efectos de los fármacos , Relajantes Musculares Centrales/toxicidad , Tubo Neural/efectos de los fármacos , Tubo Neural/embriología , Piridinas/toxicidad , Animales , Embrión de Pollo , Pollos , Desarrollo Embrionario/fisiología , Defectos del Tubo Neural/inducido químicamente , Defectos del Tubo Neural/patología
5.
J Med Toxicol ; 12(4): 406-407, 2016 12.
Artículo en Inglés | MEDLINE | ID: mdl-27234296

RESUMEN

The following unique case demonstrates an episode of acute dyskinesia secondary to oral baclofen toxicity. We discuss an 80-year-old man with a history of Stage III chronic kidney disease, coronary artery disease, diabetes and stroke who presented to the Emergency Department with new onset of behavioral changes and irregular jerking movements. The patient had been recently prescribed baclofen 10mg twice daily for a back strain he suffered; he subsequently was admitted to the hospital, and his symptoms resolved within 48 hours of admission and discontinuance of baclofen.


Asunto(s)
Dolor de Espalda/tratamiento farmacológico , Baclofeno/toxicidad , Discinesia Inducida por Medicamentos/etiología , Relajantes Musculares Centrales/toxicidad , Polifarmacia , Anciano de 80 o más Años , Dolor de Espalda/complicaciones , Baclofeno/sangre , Baclofeno/uso terapéutico , Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Diabetes Mellitus/tratamiento farmacológico , Interacciones Farmacológicas , Tasa de Filtración Glomerular , Humanos , Tiempo de Internación , Masculino , Relajantes Musculares Centrales/uso terapéutico , Insuficiencia Renal Crónica/tratamiento farmacológico , Accidente Cerebrovascular/tratamiento farmacológico
6.
Res Vet Sci ; 103: 119-25, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-26679806

RESUMEN

In contrast to humans and dogs, diazepam has been reported to induce severe hepatic side effects in cats, particularly after repeated dosing. With the aim to elucidate the mechanisms underlying this apparent sensitivity of cats to drug-induced liver injury, in a series of in vitro experiments, the feline-specific biotransformation of diazepam was studied with liver microsomes obtained from cats and dogs and the possible inhibition of the bile salt export pump (Bsep) was measured in isolated membrane vesicles overexpressing feline and canine Bsep. In line with previous in vivo studies, the phase I metabolites nordiazepam, temazepam and oxazepam were measurable in microsomal incubations, although enzyme velocity of demethylases and hydroxylases differed significantly between cats and dogs. In cats, the main metabolite was temazepam, which also could be glucuronidated. In contrast to dogs, no other glucuronidated metabolites could be observed. In addition, in the membrane vesicles an inhibition of the transport of the Bsep substrate taurocholic acid could be observed in the presence of diazepam and its metabolites. It was concluded that both mechanisms, the slow biotransformation of diazepam as well the inhibition of the bile acid efflux that results in an accumulation of bile acids in the hepatocytes, seem to contribute to the liver injury observed in cats following repetitive treatment with diazepam.


Asunto(s)
Gatos/metabolismo , Enfermedad Hepática Inducida por Sustancias y Drogas , Diazepam/farmacocinética , Diazepam/toxicidad , Perros/metabolismo , Transportadoras de Casetes de Unión a ATP/metabolismo , Animales , Anticonvulsivantes/farmacocinética , Anticonvulsivantes/toxicidad , Biotransformación , Microsomas Hepáticos/metabolismo , Relajantes Musculares Centrales/farmacocinética , Relajantes Musculares Centrales/toxicidad
7.
Prescrire Int ; 24(163): 214, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-26417633

RESUMEN

A comparison of 134 pregnant women who had taken baclofen in early pregnancy and 400 pregnant controls showed an increased risk of major malformations. Several infants exposed to baclofen until birth exhibited withdrawal symptoms.


Asunto(s)
Anomalías Inducidas por Medicamentos/etiología , Baclofeno/toxicidad , Relajantes Musculares Centrales/toxicidad , Síndrome de Abstinencia Neonatal/etiología , Efectos Tardíos de la Exposición Prenatal/inducido químicamente , Animales , Baclofeno/administración & dosificación , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Recién Nacido , Relajantes Musculares Centrales/administración & dosificación , Embarazo
8.
Int. j. morphol ; 32(2): 426-431, jun. 2014. ilus
Artículo en Inglés | LILACS | ID: lil-714286

RESUMEN

Diazepam (DZ) is a benzodiazepine that belongs to the group of minor tranquilizers with myo-relaxing and anticonvulsant properties. DZ and its metabolites cross the placental barrier in human, monkey, hamster, and mouse, and accumulate in the placenta. Our aim was to investigate, through histological techniques, and semifine sections if DZ induces morphological changes in the placenta. Twenty female mice of the ICR strain were distributed randomly in two groups. One group (DZ) was treated from days 6 to 17 of gestation with a single daily subcutaneous (sc) dose of DZ of 2.7 mg/kg/ (bw); the second, control group (C) was treated with saline solution. All females (10 DZ and 10 C) were killed by decapitation. Placentas were extracted and fixed in phosphates-buffered 10% formaldehyde, pH 7.3, dehydrated, and embedded in paraffin to obtain 3 µm thick sections or fixed in 2.5% glutaraldehyde, post-fixed in 1% OsO4, embedded in epoxy resin. Histological sections were stained with hematoxylin-eosin or Weigert´s iron hematoxylin. Semifine sections were stained with toluidine blue. All sections were observed under comparative light microscopy. The DZ-group showed thinned placental barrier with multiple vacuoles. Nuclei of trophoblast cells (TCs) and trophoblast giant cells (TGCs) presented heterochromatin in coarse granules, atypically distributed in the karyolymph and conspicuous nucleoli. The cytoplasm of the TGCs was vacuolated and chromatin had a similar appearance to that observed in TCs. The total area of the placental barrier was measured in µm2/µm2; the area in the DZ group was reduced as compared with the C group (P<0.001). Alterations of TGCs could be due to an interaction of DZ with peripheral type benzodiazepine receptors involved in progesterone biosynthesis. Administration of DZ in mice alters the placental barrier and TGCs which could affect their physiology and causes teratogenic effects on the ovary and testis involved in steroid hormones biosynthesis.


El diazepam (DZ) es una benzodiazepina que forma parte de los tranquilizantes menores con propiedades miorrelajantes y anticonvulsivantes. El DZ y sus metabolitos atraviesan la barrera placentaria en el humano, mono, hámster y ratón, y se acumula en ésta. Nuestro propósito fue investigar a través de técnicas histológicas y en cortes semifinos si el DZ induce cambios morfológicos en la placenta de ratón. Hembras de ratón de la cepa ICR se distribuyeron al azar en dos grupos. Un grupo (DZ) fue tratado del día 6 al 17 de la gestación con dosis únicas diarias subcutáneas (sc) de DZ de 2.7 mg/kg (pc); el segundo grupo control (C) se trató con solución salina. Todas las hembras (10 DZ y 10 C), se sacrificaron por decapitación. Se extrajeron las placentas y se fijaron en formaldehido al 10% amortiguado con fosfatos pH 7.3, se deshidrataron y se incluyeron en parafina para obtener cortes de 3 µm, o se fijaron en glutaraldehido al 2.5%, se posfijaron en OsO4 al 1% y se embebieron en resina epóxica. Los cortes histológicos se tiñeron con hematoxilina-eosina o con hematoxilina férrica de Weigert. Los cortes semifinos se tiñeron con azul de toluidina. Todos los cortes se observaron en un microscopio óptico de comparación. El grupo DZ presentó en la barrera placentaria múltiples vacuolas. Los núcleos de las células del trofoblasto y las células trofoblásticas gigantes (TGCs) presentaron heterocromatina en grumos gruesos, distribuidos atípicamente en la cariolinfa y nucléolos conspicuos. El citoplasma de las TGCs estaba vacuolizado y la cromatina tenía una apariencia similar a la observada en las células trofoblásticas. El área total de la barrera placentaria se midió en µm2/mm2; el área en el grupo DZ era reducida en comparación del grupo C (P<0.001). Las alteraciones de las células trofoblásticas y de las TGCs podrían deberse a la interacción del DZ con los receptores benzodiazepínicos de tipo periférico involucrados en la biosíntesis de progesterona. La administración de DZ en el ratón altera la barrera placentaria y las TGCs que podrían afectar su fisiología y causar efectos teratogénicos en el ovario y el testículo involucrados en la biosíntesis de las hormonas esteroides.


Asunto(s)
Animales , Masculino , Femenino , Embarazo , Ratones , Placenta/efectos de los fármacos , Diazepam/toxicidad , Feto/efectos de los fármacos , Relajantes Musculares Centrales/toxicidad , Placenta/patología , Trofoblastos/efectos de los fármacos , Ratones Endogámicos ICR
9.
Br J Clin Pharmacol ; 76(6): 973-9, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23594200

RESUMEN

AIMS: To ascertain the effects of the Medicines and Healthcare products Regulatory Agency's (MHRA) safety update in June 2010 on the volume of prescribing of quinine and on indices of quinine toxicity. METHODS: We analysed quarterly primary care total and quinine prescribing data for England and quinine prescribing volume for individual Primary Care Trusts in the North East of England from 2007/8 to 2011/12 obtained from the ePACT.net database. We also analysed quinine toxicity enquiries to the National Poisons Information Service (NPIS) via Toxbase(®) and by telephone between 2004/5 and 2011/12. Joinpoint regression and Pearson's correlation tests were used to ascertain changes in trends in prescribing and indices of toxicity and associations between prescribing and indices of toxicity, respectively. RESULTS: Total prescribing continued to increase, but annual growth in quinine prescribing in England declined from 6.0 to -0.6% following the MHRA update [difference -0.04 (95% confidence interval -0.07 to -0.01) quinine prescriptions per 100 patients per quarter, P = 0.0111]. Much larger reductions were observed in Primary Care Trusts that introduced comprehensive prescribing reviews. The previously increasing trend in Toxbase(®) quinine searches was reversed [difference -19.76 (95% confidence interval -39.28 to -9.20) user sessions per quarter, P = 0.0575]. Telephone enquiries to NPIS for quinine have declined, with stabilization of the proportion of moderate to severe cases of quinine poisoning since the update. CONCLUSIONS: The MHRA advice was followed by limited reductions in the growth in quinine prescribing and in indicators of quinine overdose and toxicity. Quinine prescribing, however, remains common, and further efforts are needed to reduce availability and use.


Asunto(s)
Sistemas de Registro de Reacción Adversa a Medicamentos , Medicina Clínica , Prescripciones de Medicamentos/estadística & datos numéricos , Relajantes Musculares Centrales/toxicidad , Quinina/toxicidad , Sistemas de Registro de Reacción Adversa a Medicamentos/legislación & jurisprudencia , Medicina Clínica/legislación & jurisprudencia , Medicina Clínica/tendencias , Bases de Datos Farmacéuticas , Inglaterra , Legislación de Medicamentos , Guías de Práctica Clínica como Asunto , Factores de Tiempo
10.
J Cardiovasc Pharmacol Ther ; 17(1): 102-9, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21317414

RESUMEN

BACKGROUND: Tizanidine (Zanaflex) is a centrally acting imidazoline muscle relaxant that is structurally similar to clonidine (α(2)-adrenergic agonist) but not to other myorelaxants such as baclofen or benzodiazepines. Interestingly, cardiac arrhythmias and QT interval prolongation have been reported with tizanidine. OBJECTIVE: To evaluate the effects of tizanidine on cardiac ventricular repolarization. METHODS: (1) Whole-cell patch-clamp experiments: HERG- or KCNQ1+KCNE1-transfected cells were exposed to tizanidine 0.1-100 µmol/L (n = 29 cells, total) to assess drug effect on the rapid (I(Kr)) and slow (I(Ks)) components of the delayed rectifier potassium current. (2) Langendorff retroperfusion experiments: isolated hearts from male Hartley guinea pigs (n = 6) were exposed to tizanidine 1 µmol/L to assess drug-induced prolongation of monophasic action potential duration measured at 90% repolarization (MAPD(90)). (3) In vivo wireless cardiac telemetry experiments: guinea pigs (n = 6) implanted with radio transmitters were injected a single intraperitoneal (ip) dose of tizanidine 0.25 mg/kg and 24 hours electrocardiography (ECG) recordings were made. RESULTS: (1) Patch-clamp experiments revealed an estimated IC(50) for tizanidine on I(Kr) above 100 µmol/L. Moreover, tizanidine 1 µmol/L had hardly any effect on I(Ks) (5.23% ± 4.54% inhibition, n = 5 cells). (2) While pacing the hearts at stimulation cycle lengths of 200 or 250 ms, tizanidine 1 µmol/L prolonged MAPD(90) by 8.22 ± 2.03 (6.7%) and 11.70 ± 3.08 ms (8.5%), respectively (both P < .05 vs baseline). (3) Tizanidine 0.25 mg/kg ip caused a maximal 11.93 ± 1.49 ms prolongation of corrected QT interval (QTc), 90 minutes after injection. CONCLUSION: Tizanidine prolongs the QT interval by blocking I(Kr). Patients could be at risk of cardiac proarrhythmia during impaired drug elimination, such as in case of CYP1A2 inhibition during drug interactions.


Asunto(s)
Clonidina/análogos & derivados , Síndrome de QT Prolongado/inducido químicamente , Relajantes Musculares Centrales/farmacología , Bloqueadores de los Canales de Potasio/farmacología , Canales de Potasio con Entrada de Voltaje/antagonistas & inhibidores , Animales , Células CHO , Clonidina/farmacología , Clonidina/toxicidad , Cricetinae , Cricetulus , Relación Dosis-Respuesta a Droga , Cobayas , Células HEK293 , Corazón , Humanos , Síndrome de QT Prolongado/fisiopatología , Masculino , Relajantes Musculares Centrales/toxicidad , Bloqueadores de los Canales de Potasio/toxicidad , Canales de Potasio con Entrada de Voltaje/fisiología
11.
J Eur Acad Dermatol Venereol ; 26(6): 680-4, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21692868

RESUMEN

BACKGROUND: Tetrazepam, a benzodiazepine, is a frequently used muscle relaxant. The most common adverse reactions are neurological and gastrointestinal. Cutaneous reactions to tetrazepam are rare and occur predominantly after systemic administration. OBJECTIVE: To present 10 health care professionals who developed airborne contact dermatitis to tetrazepam due to occupational exposure to tetrazepam dusts. MATERIALS AND METHODS: We report a series of 10 cases observed in our department between January 2006 and March 2011 where tetrazepam was identified to cause allergic airborne contact dermatitis. Affected individuals were employed as (geriatric) nursing staff, exposed to tetrazepam on a regular occupational basis when crushing tablets for their patients. Upon investigation, patients were patch tested with commercial and customized allergens. This included tetrazepam and in five cases diazepam. Tetrazepam revealed strong positive reactions in all patients. Additional diazepam sensitization was observed in three subjects. Following local treatment and occupational preventive action, patients recovered from their skin symptoms. CONCLUSIONS: Allergic contact sensitization to tetrazepam and cross-sensitization to diazepam seems to be underestimated and not appropriately diagnosed in patch test clinics, as it is so far insufficiently patch tested. They should be considered when allergic contact dermatitis is suspected, particularly in professionally exposed staff, and tested as supplemental allergens.


Asunto(s)
Contaminantes Ocupacionales del Aire/toxicidad , Benzodiazepinas/toxicidad , Dermatitis por Contacto/etiología , Enfermería Geriátrica , Relajantes Musculares Centrales/toxicidad , Enfermeras y Enfermeros , Exposición Profesional , Humanos , Recursos Humanos
12.
Behav Pharmacol ; 22(7): 718-22, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21921842

RESUMEN

There is increasing concern about abuse of propofol, a widely-used surgical anesthetic and sedative that is currently not a controlled substance. The purpose of this study was to establish a rat model of the psychoactive effect of subanesthetic doses of propofol that could be useful for confirming abuse liability and for studying mechanisms of propofol abuse. Sprague-Dawley rats were trained to discriminate propofol (10 mg/kg, intraperitoneally) from vehicle (2% methylcellulose). Carisoprodol (100 mg/kg), chlordiazepoxide (10 mg/kg), and dizocilpine (0.1 mg/kg) were tested for substitution for the discriminative-stimulus effects of propofol (10 mg/kg), whereas pentylenetetrazol (10 mg/kg) was tested for antagonism of the discriminative-stimulus effects. Propofol (10 mg/kg) was tested for substitution in rats trained to discriminate carisoprodol from vehicle. Carisoprodol produced 59% propofol-appropriate responding, chlordiazepoxide produced 65% propofol-appropriate responding, and dizocilpine produced 34% propofol-appropriate responding. Pentylenetetrazol decreased propofol-appropriate responding to 41%. Propofol produced 52% carisoprodol-appropriate responding. Mortality rate during training of propofol (10 mg/kg) was 38%. Postmortem examination revealed cardiovascular abnormalities similar to those observed in propofol-infusion syndrome in humans. The results demonstrate that propofol can be trained as a discriminative stimulus. Its discriminative-stimulus effects were more similar to compounds promoting γ-aminobutyric acid-A receptor activity than to a compound inhibiting N-methyl-d-aspartate receptor activity. As propofol has discriminative-stimulus effects similar to known drugs of abuse, and occasions a high-mortality rate, its potential for continued abuse is of particular concern.


Asunto(s)
Conducta Animal/efectos de los fármacos , Carisoprodol/toxicidad , Depresores del Sistema Nervioso Central/toxicidad , Hipnóticos y Sedantes/toxicidad , Relajantes Musculares Centrales/toxicidad , Propofol/toxicidad , Animales , Carisoprodol/farmacología , Carisoprodol/envenenamiento , Depresores del Sistema Nervioso Central/farmacología , Depresores del Sistema Nervioso Central/envenenamiento , Discriminación en Psicología , Maleato de Dizocilpina/farmacología , Relación Dosis-Respuesta a Droga , Antagonistas del GABA/farmacología , Hipnóticos y Sedantes/farmacología , Hipnóticos y Sedantes/envenenamiento , Masculino , Actividad Motora , Relajantes Musculares Centrales/farmacología , Relajantes Musculares Centrales/envenenamiento , Pentilenotetrazol/farmacología , Propofol/farmacología , Propofol/envenenamiento , Ratas , Ratas Sprague-Dawley , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidores
13.
J Pharmacol Toxicol Methods ; 62(1): 30-9, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20507819

RESUMEN

INTRODUCTION: A novel automated blood sampling and telemetry (ABST) system was developed to integrate pharmacokinetic (PK), pharmacodynamic (PD) and toxicology studies. The goals of this investigation were to determine: 1) optimal feeding conditions and minimal acclimation times for recording PD parameters (blood pressure, heart rate, and temperature) after animals arrived on-site; 2) stress hormone levels in ABST-housed rats; 3) the feasibility of simultaneously recording cardiovascular parameters with electroencephalogram (EEG); 4) the equivalence of renal endpoints from ABST-housed rats with those in the metabolic cage, and 5) the cardiovascular responses to baclofen. METHODS: Body weight, blood pressure, temperature, stress biomarkers, urine chemistries, renal biomarkers and responses to vehicle or baclofen (10mg/kg) were compared in awake and freely moving rats housed in the ABST system, home cage (HC) or metabolic cage. RESULTS: Fasted rats lost 5+/-1% and 7+/-1% body weight when housed in ABST and metabolic cages, respectively. Weight loss was reversed by supplementing regular diet with hydration and nutritional supplements. Based on PD parameters, the minimum acclimation time required for both ABST and HC rats was 3days. The feasibility of simultaneously measuring multiple parameters, such as EEG with cardiovascular parameters in ABST was demonstrated. Renal function and biomarkers in rats continuously housed in the ABST and metabolic cages were equivalent (p>0.05) on days 1, 3, and 7. Baclofen-induced quantitatively and qualitatively similar (p>0.05) PK, mean arterial pressure, heart rate and temperature in ABST- and HC-housed rats. DISCUSSION: These studies demonstrate for the first time that drug-induced PD responses can be recorded simultaneously with time-matched pharmacokinetic, biochemical and metabolic parameters in the same animal. The ABST system has the added advantage of blood sampling without the need for satellite PK animals. ABST is a useful and novel tool for establishing efficacy and safety margins using an in vivo integrative pharmacology approach.


Asunto(s)
Baclofeno/farmacología , Recolección de Muestras de Sangre , Relajantes Musculares Centrales/farmacología , Animales , Automatización , Baclofeno/administración & dosificación , Baclofeno/sangre , Baclofeno/toxicidad , Presión Sanguínea/efectos de los fármacos , Temperatura Corporal/efectos de los fármacos , Electrodos Implantados/veterinaria , Electroencefalografía/efectos de los fármacos , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Hormonas/sangre , Riñón/química , Masculino , Relajantes Musculares Centrales/administración & dosificación , Relajantes Musculares Centrales/sangre , Relajantes Musculares Centrales/toxicidad , Ratas , Ratas Wistar , Telemetría/veterinaria , Orina/química
14.
Brain Res ; 1321: 78-87, 2010 Mar 19.
Artículo en Inglés | MEDLINE | ID: mdl-20097183

RESUMEN

A large number of commercially available drugs are known to cause visual side effects in humans. Therefore, it would be advantageous to screen for alterations in visual function at a pre-clinical stage. Available methods, however, lack control for motivational and motoric side effects. The aim of the present study was therefore to develop a behavioural test to detect and quantify drug-induced visual side effects while simultaneously controlling for other side effects. We here present a novel model based on operant conditioning methodology with a food rewarded two-choice design to assess visual acuity and contrast sensitivity in rats. Rats were trained to discriminate between computer-generated sine-wave gratings and homogenous grey stimuli of equal luminance. They were subsequently tested with novel stimuli differing to training stimuli according to either spatial frequency or contrast. Finally, we tested how visual acuity was affected by oral administration of quinine HCl, a compound known to affect visual function in man. The rats learned to discriminate visual stimuli within 4-5weeks of twice daily training. A training procedure with moving stimuli achieved faster learning than with static stimuli. The visual detection threshold for discrimination of grating patterns decreased as a function of the contrast level, ranging from a spatial frequency of 0.8cycles/degree (c/d) at 100% contrast to 0.2c/d at 12.5%. Administration of quinine HCl was shown to affect the visual acuity threshold in a dose- and time dependent manner. In addition, response rate was affected by quinine administration but temporally isolated from the attenuation of visual acuity demonstrating that this model can separate the visual effects from motoric and motivational side effects.


Asunto(s)
Condicionamiento Operante , Sensibilidad de Contraste/efectos de los fármacos , Evaluación Preclínica de Medicamentos/métodos , Agudeza Visual/efectos de los fármacos , Animales , Conducta Animal/efectos de los fármacos , Condicionamiento Operante/efectos de los fármacos , Discriminación en Psicología/efectos de los fármacos , Masculino , Relajantes Musculares Centrales/toxicidad , Quinina/toxicidad , Ratas , Ratas Long-Evans , Ratas Wistar
15.
Epileptic Disord ; 11(4): 329-32, 2009 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-19995690

RESUMEN

Acetaminophen is a widely used analgesic that can cause acute liver failure when consumed above a maximum daily dose. Certain patients may be at increased risk of hepatocellular damage even at conventional therapeutic doses. We report a case of a 34-year-old man on carbamazepine for complex partial seizures who developed acute liver and renal failure on less than 2.5 grams a day of acetaminophen. This raises caution that patients on carbamazepine should avoid chronic use of acetaminophen, and if required use at lower doses with vigilant monitoring for signs of liver damage.


Asunto(s)
Acetaminofén/toxicidad , Analgésicos no Narcóticos/toxicidad , Anticonvulsivantes/toxicidad , Dolor de Espalda/tratamiento farmacológico , Carbamazepina/toxicidad , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Epilepsia Parcial Compleja/tratamiento farmacológico , Metocarbamol/toxicidad , Relajantes Musculares Centrales/toxicidad , Acetaminofén/administración & dosificación , Adulto , Analgésicos no Narcóticos/administración & dosificación , Anticonvulsivantes/administración & dosificación , Carbamazepina/administración & dosificación , Enfermedad Hepática Inducida por Sustancias y Drogas/diagnóstico , Clonazepam/administración & dosificación , Clonazepam/toxicidad , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Quimioterapia Combinada , Humanos , Pruebas de Función Hepática , Masculino , Metocarbamol/administración & dosificación , Relajantes Musculares Centrales/administración & dosificación , Nefritis Intersticial/inducido químicamente , Nefritis Intersticial/diagnóstico , Examen Neurológico/efectos de los fármacos
17.
CNS Neurosci Ther ; 14(2): 107-19, 2008.
Artículo en Inglés | MEDLINE | ID: mdl-18482024

RESUMEN

Tolperisone, a piperidine derivative, is assigned to the group of centrally acting muscle relaxants and has been in clinical use now for decades. The review summarizes the known pharmacokinetics, pharmacodynamics, toxicology and side effects in humans and the clinical use of tolperisone. A future perspective for further exploration of this drug is given.


Asunto(s)
Relajantes Musculares Centrales/farmacología , Tolperisona/farmacología , Animales , Ensayos Clínicos como Asunto , Humanos , Hipnóticos y Sedantes , Relajantes Musculares Centrales/efectos adversos , Relajantes Musculares Centrales/metabolismo , Relajantes Musculares Centrales/farmacocinética , Relajantes Musculares Centrales/toxicidad , Tolperisona/efectos adversos , Tolperisona/metabolismo , Tolperisona/farmacocinética , Tolperisona/toxicidad
19.
J Neurosurg ; 107(3 Suppl): 225-7, 2007 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-17918530

RESUMEN

OBJECT: This study was designed to evaluate the clinical and histopathological effects of long-term (3-month) intraventricular baclofen (IVB) infusion in beagle dogs. METHODS: Catheters were inserted stereotactically into the lateral ventricles of nine dogs and were connected to implanted Synchromed II pumps. Saline solution (control animals) and IVB (experimental animals) were infused continuously. The IVB dosages ranged from 100 to 1000 microg/day. RESULTS: An IVB infusion of 135 microg/day or less throughout a 3-month period was associated with no adverse side effects in any animal. Infusion of 150 microg/day produced overt seizures in one dog and produced adverse side effects in another; a reduction in the dosage given to these animals to 135 microg/day was tolerated with no adverse effects. Infusion of IVB at a dosage of 250, 500, or 1000 microg/day caused lethal toxicity within the first 4 days of infusion. Histopathological specimens obtained at necropsy revealed no ventricular or subependymal changes in animals receiving an IVB dosage of 135 microg/day or less. CONCLUSIONS: Intraventricular baclofen infusion in beagles has dose-related toxicity; however, no clinical or neurological toxicity was evidenced at clinically tolerated dosages (< or =135 microg/day) throughout 3 months of infusion.


Asunto(s)
Baclofeno/toxicidad , Relajantes Musculares Centrales/toxicidad , Animales , Baclofeno/farmacología , Encéfalo/patología , Líquido Cefalorraquídeo/metabolismo , Perros , Relación Dosis-Respuesta a Droga , Femenino , Cuarto Ventrículo , Bombas de Infusión , Inyecciones Intraventriculares , Inyecciones Espinales , Imagen por Resonancia Magnética , Masculino , Modelos Animales , Relajantes Musculares Centrales/farmacología , Factores de Tiempo
20.
Proc Natl Acad Sci U S A ; 102(35): 12531-6, 2005 Aug 30.
Artículo en Inglés | MEDLINE | ID: mdl-16109766

RESUMEN

Peroxisome proliferator-activated receptor-binding protein (PBP), also known as thyroid hormone receptor-associated protein 220/vitamin D receptor-interacting protein 205/mediator 1, an anchor for multisubunit mediator transcription complex, functions as a transcription coactivator for nuclear receptors. Disruption of the PBP gene results in embryonic lethality around embryonic day 11.5 by affecting placental and multiorgan development. Here, we report that targeted deletion of PBP in liver parenchymal cells (PBP(Liv-/-)) results in the abrogation of hypertrophic and hyperplastic influences in liver mediated by constitutive androstane receptor (CAR) ligands phenobarbital (PB) and 1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene, and of acetaminophen-induced hepatotoxicity. CAR interacts with the two nuclear receptor-interacting LXXLL (L, leucine; X, any amino acid) motifs in PBP in a ligand-dependent manner. We also show that PBP interacts with the C-terminal portion of CAR, suggesting that PBP is involved in the regulation of CAR function. Although the full-length PBP only minimally increased CAR transcriptional activity, a truncated form of PBP (amino acids 487-735) functioned as a dominant negative repressor, establishing that PBP functions as a coactivator for CAR. A reduction in CAR mRNA and protein level observed in PBP(Liv-/-) mouse liver suggests that PBP may regulate hepatic CAR expression. PBP-deficient hepatocytes in liver failed to reveal PB-dependent translocation of CAR to the nucleus. Adenoviral reconstitution of PBP in PBP(Liv-/-) mouse livers restored PB-mediated nuclear translocation of CAR as well as inducibility of CYP1A2, CYP2B10, CYP3A11, and CYP7A1 expression. We conclude that transcription coactivator PBP/TRAP220/MED1 is involved in the regulation of hepatic CAR function and that PBP deficiency in liver abrogates acetaminophen hepatotoxicity.


Asunto(s)
Acetaminofén/toxicidad , Hígado/efectos de los fármacos , Hígado/metabolismo , Factores de Transcripción/deficiencia , Animales , Secuencia de Bases , Receptor de Androstano Constitutivo , ADN/genética , ADN/metabolismo , Expresión Génica , Hiperplasia , Hipertrofia , Hígado/patología , Subunidad 1 del Complejo Mediador , Ratones , Ratones Noqueados , Relajantes Musculares Centrales/toxicidad , Parálisis/inducido químicamente , Receptores Activados del Proliferador del Peroxisoma/metabolismo , Receptores Citoplasmáticos y Nucleares/agonistas , Receptores Citoplasmáticos y Nucleares/metabolismo , Factores de Transcripción/agonistas , Factores de Transcripción/genética , Factores de Transcripción/metabolismo , Zoxazolamina/toxicidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...